In addition, we developed a promising enhanced antiangiogenic and antitumour strategy by using the application of the RGD (a ligand of αvβ3 integrin)‐VEGI‐192 fusion protein, leading to a combination therapy against multiple tumour‐targets.9 The gene discussed is TNFSF15; the disease is neoplasm.